BORTEZOMIB 1 mg/1 (Bortezomib INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 1 mg/1

Bortezomib 1 mg/1 is a lyophilized powder injection used for targeted therapeutic applications. This single-dose vial is manufactured by Hospira, Inc. and is suitable for intravenous or subcutaneous administration.

Strength

1 mg/1

Pack Size

1 VIAL, SINGLE-DOSE in 1 CARTON (0409-1704-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in

Manufacturer / TM Owner

Hospira, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Bortezomib 1 mg/1 is primarily used in the management of certain hematological malignancies. This medication works by inhibiting proteasome activity, which can affect the growth of cancer cells. It is often prescribed as part of a broader treatment plan for conditions where targeted therapy is beneficial.

Side Effects

Common effects of Bortezomib 1 mg/1 may include fatigue, nausea, and peripheral neuropathy. Some individuals might experience gastrointestinal disturbances or low blood cell counts. These effects can vary depending on the individual and the specific treatment regimen.

Precautions & Warnings

Bortezomib 1 mg/1 should be handled with care, ensuring proper storage and administration techniques. It is important to follow healthcare provider instructions regarding dosage and administration routes. Patients should be monitored for any adverse reactions and report them promptly.

Avoid Interactions

Bortezomib 1 mg/1 may interact with other medications, including those that affect liver enzymes or blood cell production. It is advisable to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and certain supplements may also influence the effectiveness of this medication.

Frequently Asked Questions

Bortezomib 1 mg/1 is used in the treatment of certain types of cancer, particularly hematological malignancies.

Bortezomib 1 mg/1 can be administered either intravenously or subcutaneously, depending on the prescribed treatment plan.

Common side effects may include fatigue, nausea, peripheral neuropathy, and gastrointestinal disturbances.

It is important to consult a healthcare provider before combining Bortezomib 1 mg/1 with other medications to avoid potential interactions.

Bortezomib 1 mg/1 should be stored according to the manufacturer's instructions to maintain its efficacy and safety.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.